DrugTimes BD Project DTC-059 | Dual-Action FXl/FXla Inhibitor: A Low-Bleeding，Superior-Efficacy Antibody with Best-in-Class Potential

While numerous anticoagulants with diverse mechanisms of action (e.g., Eliquis, heparin, warfarin) are currently marketed, they all target common pathway factors in the coagulation cascade. Consequently, patients face bleeding risks during anticoagulant therapy, with some experiencing life-threatening major bleeding events. There is a clear clinical need for safer and more effective next-generation anticoagulants that maintain therapeutic efficacy while reducing or eliminating bleeding risks.

On February 11, 2025, Novartis announced the acquisition of Anthos Therapeutics for a total transaction value of $3.1 billion, securing Abelacimab, a fully human monoclonal antibody targeting Factor XI (FXI). Compared to the active comparator Xarelto (rivaroxaban, a Factor Xa inhibitor), Abelacimab demonstrated superior efficacy and reduced bleeding risk in Phase II clinical trials. Abelacimab reduced the incidence of major or clinically relevant non-major bleeding by 62%, major bleeding by 67%, and gastrointestinal bleeding by 89%. These data validate FXI as a promising target for anticoagulation therapy, with clinical proof-of-concept established. Abelacimab holds significant potential for preventing thrombosis while reducing the risk of clinically relevant bleeding.

Furthermore, as an antibody therapeutic, Abelacimab avoids hepatic and renal metabolic pathways typical of small molecules, thereby minimizing drug-drug interactions and individual variability. Abelacimab is administered as a monthly intravenous injection, offering enhanced patient compliance and convenience compared to daily oral dosing required for apixaban and rivaroxaban.

The Yaoshidai BD team is currently seeking potential partners for an innovative FXI bispecific antibody targeting dual epitopes, which demonstrates best-in-class (BIC) potential and a low bleeding risk profile.

Project Code: DT-20250622-059
Project Name: Dual-Action FXl/FXla Inhibitor: A Low-Bleeding，Superior-Efficacy Antibody with Best-in-Class Potential
Indications: Venous Thromboembolism (VTE), Atrial Fibrillation (AF)
Drug Type: Humanized Antibody
Target: FXI and FXIa
Development Stage: PCC (Preclinical Candidate) Completed; Cell Line Development Ongoing

Key Highlights:

• Differentiated Mechanism: First-in-class FXI bispecific antibody targeting both the A2 and catalytic domains (CD), demonstrating synergistic effects for high efficacy and low bleeding risk.

• A BIC prolonged APTT ratio of approximately 3

• Sustained Anticoagulant Effect: Maintained for over one month.
• Blockbuster Potential: Targets the multi-billion dollar global anticoagulant market with the potential to significantly reduce bleeding risks associated with current therapies.

Colaboration: License-out (ex-China)

Contact us:

For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!